AptarGroup (NYSE:ATR) FY Conference Transcript

Summary of AptarGroup FY Conference Call (March 03, 2026) Company Overview - Company: AptarGroup (NYSE:ATR) - Industry: Drug and consumer product packaging - Core Business: Design and manufacturing of dosing, dispensing, and protection technologies, with a focus on proprietary intellectual property [3][4] Financial Performance - 2025 Revenue: Approximately $3.8 billion - Pharma Segment: 46% of revenue, 70% of adjusted EBITDA - Beauty Segment: 35% of revenue, 18% of adjusted EBITDA - Closures Segment: 19% of revenue, 13% of adjusted EBITDA [4] - Capital Return: $1.2 billion returned to shareholders over the last five years through dividends and share buybacks [6][14] - Leverage Ratio: 1.38x EBITDA, at the low end of the 1-3x corridor [5] Market Segments and Growth Opportunities - Pharma Segment: - Total Addressable Market (TAM): $165 billion, projected 7% CAGR - Revenue CAGR over the last 10 years: 9% [11][22] - Key products: Proprietary drug delivery systems (70% of pharma revenue), injectables (19%), active material science solutions (10%) [17] - Strong pipeline in respiratory, biologics, and systemic nasal drug delivery [24][25] - Beauty Segment: - Revenue: $1.3 billion in 2025, with 60% of sales in Europe - Growth: 7% total sales growth, 2% core sales growth [35][38] - Focus on innovation and serving both major and indie brands [38] - Closures Segment: - Revenue: $700 million, with 2% reported growth and 1% core growth [39] - Strong product volume growth of 4% when isolating resin pass-through impacts [41] Innovation and Technology - Intellectual Property: Over 7,300 patents, with 62% in pharma [10][18] - Sustainability Leadership: Recognized for sustainability efforts, which attract customers and talent [15][16] - AI and Digital Health: Incorporating AI for advanced analytics to enhance service offerings and strengthen customer relationships [53][54] Strategic Focus - Investment Strategy: Approximately two-thirds of capital returned to business through organic CapEx and M&A, with a focus on the pharma segment [13][14] - Long-term Revenue Growth Target: 4%-7% total revenue growth, supported by market growth projections [12][29] - Customer Engagement: Building relationships from the design phase through to patient engagement, enhancing revenue stickiness [30][32] Key Challenges and Considerations - Emergency Medicine Reset: Acknowledged impact on pharma growth, but overall strong growth in other areas [41] - Market Dynamics: Transition from high GWP to low GWP propellants in inhalers, with regulatory pressures influencing growth [46][47] Conclusion - Outlook: Positive growth trajectory across all segments, with a strong emphasis on innovation, sustainability, and leveraging technology to enhance customer value and operational efficiency [42][54]